Chong Kun Dang Pharmaceutical Corp.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. carries a market capitalization of 872.26B, placing it among publicly traded companies globally. Its enterprise value stands at 983.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chong Kun Dang Pharmaceutical Corp.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. has 13.18M shares outstanding.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. trades at a trailing price-to-earnings ratio of 10.98. The price-to-sales ratio is 0.49, and the price-to-book ratio stands at 0.86.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. trades at an EV/EBITDA multiple of 8.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 12.74 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 983.25B versus a market cap of 872.26B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.96, indicating elevated leverage, while an interest coverage ratio of 15.52 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chong Kun Dang Pharmaceutical Corp. posted a return on equity (ROE) of 8.24, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.72, measuring how efficiently the asset base is converted into earnings. The company generates approximately 771.12M in revenue per employee across its workforce of 2,312.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.05 indicates how many times Chong Kun Dang Pharmaceutical Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chong Kun Dang Pharmaceutical Corp. recorded an income tax benefit of -2.71B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 76.86B, leaving 79.47B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Chong Kun Dang Pharmaceutical Corp.'s stock has declined approximately 19.43% over the past 52 weeks. The 50-day moving average sits at 66,816.00, while the 200-day moving average is 77,358.50.

Over the twelve months ended June 30, 2026, Chong Kun Dang Pharmaceutical Corp. generated 1.78T in revenue and converted that into 79.47B in net income, yielding earnings per share of 6,038.26. EBITDA reached 122.95B, while operating income came in at 77.17B.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. holds 329.30B in cash and equivalents against 437.44B in total debt, resulting in a net debt position of 236.03B. Total book value stands at 1.02T, with working capital of 550.30B providing operational flexibility.

Chong Kun Dang Pharmaceutical Corp. produced 123.26B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -252.05B in capital expenditures, free cash flow totaled -128.79B - equivalent to -9,774.29 per share.

Over the twelve months ended June 30, 2026, Chong Kun Dang Pharmaceutical Corp. posted a gross margin of 29.79, reflecting its pricing power and cost economics. The operating margin of 4.33 and net profit margin of 4.46 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chong Kun Dang Pharmaceutical Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -14.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.13, meaning Chong Kun Dang Pharmaceutical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Chong Kun Dang Pharmaceutical Corp.'s most recent stock split took place on December 27, 2024 with a 20:21 split ratio.

As of June 30, 2026, Chong Kun Dang Pharmaceutical Corp. has an Altman Z-Score of 2.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.